Adjuvant Nivolumab: A New Standard of Care in High-risk MIUC? ...Middle East

Nivolumab is efficacious and well tolerated when used as adjuvant therapy in patients who have undergone radical surgery for high-risk, muscle-invasive urothelial carcinoma, new research suggests. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Adjuvant Nivolumab: A New Standard of Care in High-risk MIUC? )

Also on site :

• Wall Street’s advice after Nvidia hits historic $4 trillion market cap: BUY
• Google founder claims UN is ‘transparently anti-Semitic’ – WaPo
• Putin stooges DELIGHT in brazen daylight assassination of Ukrainian spy chief – and all but confirm Vlad was behind hit